About Khora Therapeutics

Khora Therapeutics is a clinical stage precision oncology company developing targeted therapies for cancer patients with high unmet medical needs. The company focuses on ensuring global access to these next-generation treatments, addressing disparities in healthcare availability worldwide.

```xml <problem> Many cancer patients with specific genetic mutations do not respond well to traditional chemotherapy or radiation, leading to poor outcomes and limited treatment options. Access to targeted therapies, which address the underlying molecular drivers of their cancer, remains a challenge, particularly in underserved regions. </problem> <solution> Khora Therapeutics is a precision oncology company focused on developing targeted therapies for cancer patients with unmet medical needs. They aim to improve treatment outcomes by creating drugs that selectively target specific genetic mutations or molecular pathways driving cancer growth. By focusing on precision medicine, Khora seeks to deliver more effective and less toxic treatments, ultimately improving the quality of life for cancer patients. Their mission includes ensuring global access to these advanced therapies, addressing disparities in healthcare availability worldwide. </solution> <features> - Development of targeted therapies designed to address specific genetic mutations in cancer cells. - Focus on precision medicine to improve treatment outcomes and reduce side effects. - Commitment to ensuring global access to next-generation oncology therapeutics. </features> <target_audience> The primary target audience includes cancer patients with specific genetic mutations who are not responding well to traditional treatments, as well as oncologists and healthcare providers seeking more effective and targeted therapies. </target_audience> ```

What does Khora Therapeutics do?

Where is Khora Therapeutics located?

Khora Therapeutics is based in Cambridge, United Kingdom.

When was Khora Therapeutics founded?

Khora Therapeutics was founded in 2024.

Location

Cambridge, United Kingdom

Founded

2024

Employees

10 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Khora Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

khoratx.com 50+

Founded 2024 – Cambridge, United Kingdom

Funding

No funding information available.

Team (10+)

No team information available.

Company Description

Problem

Many cancer patients with specific genetic mutations do not respond well to traditional chemotherapy or radiation, leading to poor outcomes and limited treatment options. Access to targeted therapies, which address the underlying molecular drivers of their cancer, remains a challenge, particularly in underserved regions.

Solution

Khora Therapeutics is a precision oncology company focused on developing targeted therapies for cancer patients with unmet medical needs. They aim to improve treatment outcomes by creating drugs that selectively target specific genetic mutations or molecular pathways driving cancer growth. By focusing on precision medicine, Khora seeks to deliver more effective and less toxic treatments, ultimately improving the quality of life for cancer patients. Their mission includes ensuring global access to these advanced therapies, addressing disparities in healthcare availability worldwide.

Features

Development of targeted therapies designed to address specific genetic mutations in cancer cells.

Focus on precision medicine to improve treatment outcomes and reduce side effects.

Commitment to ensuring global access to next-generation oncology therapeutics.

Target Audience

The primary target audience includes cancer patients with specific genetic mutations who are not responding well to traditional treatments, as well as oncologists and healthcare providers seeking more effective and targeted therapies.